Literature DB >> 15070799

Shedding light on immunotherapy for cancer.

Steven A Rosenberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15070799      PMCID： PMC2275326          DOI： 10.1056/NEJMcibr045001

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

Review 2.  Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Authors:  Hung T Khong; Nicholas P Restifo
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

3.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

4.  Priming of naive T cells inside tumors leads to eradication of established tumors.

Authors:  Ping Yu; Youjin Lee; Wenhua Liu; Robert K Chin; Jing Wang; Yang Wang; Andrea Schietinger; Mary Philip; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2004-01-04       Impact factor: 25.606

5.  Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Authors:  Willem W Overwijk; Marc R Theoret; Steven E Finkelstein; Deborah R Surman; Laurina A de Jong; Florry A Vyth-Dreese; Trees A Dellemijn; Paul A Antony; Paul J Spiess; Douglas C Palmer; David M Heimann; Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Lionel Feigenbaum; Ada M Kruisbeek; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307
  5 in total
  38 in total

1.  Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.

Authors:  Willem W Overwijk; Karin E de Visser; Felicia H Tirion; Laurina A de Jong; Thijs W H Pols; Yme U van der Velden; Jasper G van den Boorn; Anna M Keller; Wim A Buurman; Marc R Theoret; Bianca Blom; Nicholas P Restifo; Ada M Kruisbeek; Robert A Kastelein; John B A G Haanen
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

Review 2.  Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come.

Authors:  Ayesha Murshid; Jianlin Gong; Mary Ann Stevenson; Stuart K Calderwood
Journal:  Expert Rev Vaccines       Date:  2011-11       Impact factor: 5.217

3.  Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro.

Authors:  M Shi; S Qian; W-W Chen; H Zhang; B Zhang; Z-R Tang; Z Zhang; F-S Wang
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

4.  Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35.

Authors:  Arvind Chhabra; Nitya G Chakraborty; Bijay Mukherji
Journal:  Clin Immunol       Date:  2008-01-14       Impact factor: 3.969

5.  An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain.

Authors:  Verena Voelter; Alessia Pica; Julien Laurent; Donata Rimoldi; Hanifa Bouzourene; Ali Sajadi; Maurice Matter; Pedro Romero; Nathalie Rufer; Daniel E Speiser
Journal:  Cancer Immun       Date:  2008-03-27

6.  CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Authors:  Paul A Antony; Ciriaco A Piccirillo; Akgül Akpinarli; Steven E Finkelstein; Paul J Speiss; Deborah R Surman; Douglas C Palmer; Chi-Chao Chan; Christopher A Klebanoff; Willem W Overwijk; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

7.  Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.

Authors:  Chih-Hung Lee; Takashi Kakinuma; Julia Wang; Hong Zhang; Douglas C Palmer; Nicholas P Restifo; Sam T Hwang
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

8.  Identification of major histocompatibility complex class II-restricted antigens and epitopes of the Epstein-Barr virus by a novel bacterial expression cloning approach.

Authors:  Slavoljub Milosevic; Uta Behrends; Dinesh Adhikary; Josef Mautner
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

Review 9.  Clinical applications of a peptide-based vaccine for glioblastoma.

Authors:  Charles W Kanaly; Dale Ding; Amy B Heimberger; John H Sampson
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

10.  Bacteriolytic therapy can generate a potent immune response against experimental tumors.

Authors:  Nishant Agrawal; Chetan Bettegowda; Ian Cheong; Jean-Francois Geschwind; Charles G Drake; Edward L Hipkiss; Mitsuaki Tatsumi; Long H Dang; Luis A Diaz; Martin Pomper; Mohammad Abusedera; Richard L Wahl; Kenneth W Kinzler; Shibin Zhou; David L Huso; Bert Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-07       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.